{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:48:05Z","timestamp":1793756885520,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejmech.2020.112931","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T22:10:24Z","timestamp":1602627024000},"page":"112931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Polypharmacological drug actions of recently FDA approved antibiotics"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-5331","authenticated-orcid":false,"given":"Carlie","family":"Wetzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Lonneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-6298","authenticated-orcid":false,"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112931_bib1","series-title":"Targeted Therapies in Cancer","author":"Lacroix","year":"2014"},{"key":"10.1016\/j.ejmech.2020.112931_bib2","first-page":"97","article-title":"Hematopoietic stem cells: potential new applications for translational medicine","volume":"9","author":"Felfly","year":"2014","journal-title":"J.\u00a0Stem Cell."},{"key":"10.1016\/j.ejmech.2020.112931_bib3","first-page":"71","article-title":"Cardiology\u2019s 10 greatest discoveries of the 20th century","volume":"29","author":"Mehta","year":"2002","journal-title":"Tex. Heart Inst. J."},{"key":"10.1016\/j.ejmech.2020.112931_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112931_bib6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/431899a","article-title":"Antibiotics at the crossroads","volume":"431","author":"Nathan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112931_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2006.01528.x","article-title":"Impact of antibiotic restrictions: the pharmaceutical perspective","volume":"12","author":"Power","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2020.112931_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.mib.2003.08.003","article-title":"Why is big Pharma getting out of antibacterial drug discovery?","volume":"6","author":"Projan","year":"2003","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112931_bib9","first-page":"277","article-title":"The antibiotic resistance crisis, Part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"PubMed"},{"key":"10.1016\/j.ejmech.2020.112931_bib10","first-page":"10","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112931_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1381612822666160224142812","article-title":"Polypharmacology in drug discovery: a review from systems pharmacology perspective","volume":"22","author":"Zhang","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.112931_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A\u00a0perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112931_bib13","series-title":"Neuropathology of Drug Addictions and Substance Misuse Volume 3:General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse, Emerging Addictions and Non-drug Addictions","first-page":"154","author":"Preedy","year":"2016"},{"issue":"13","key":"10.1016\/j.ejmech.2020.112931_bib14","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug: multitarget drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112931_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112931_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A\u00a0perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsey","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2020.112931_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1021\/cr030103a","article-title":"Glycopeptide and lipoglycopeptide antibiotics","volume":"105","author":"Kahne","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112931_bib18","series-title":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother","article-title":"Mechanisms of action of oritavancin in Staphylococcus aureus, abstr. C1-1471","author":"Arhin","year":"2007"},{"key":"10.1016\/j.ejmech.2020.112931_bib19","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1039\/C3OB42428F","article-title":"Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin","volume":"12","author":"Cheng","year":"2014","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112931_bib20","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/AAC.05869-11","article-title":"A\u00a0novel membrane protein, VanJ, conferring resistance to teicoplanin\u201d antimicrob","volume":"56","author":"Novotn\u00e1","year":"2012","journal-title":"Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2020.112931_bib21","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112931_bib23","first-page":"49","article-title":"Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens","volume":"4","author":"Das","year":"2017","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112931_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.284.5413.442","article-title":"Deconstructing vancomycin","volume":"284","author":"Walsh","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112931_bib25","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1073\/pnas.0931492100","article-title":"Vancomycin analogues active against vanA resistant strains inhibit bacterial transglycosylase without binding substrate","volume":"100","author":"Chen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112931_bib26","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1021\/acs.jmedchem.8b01093","article-title":"Battle against vancomycin-resistant bacteria: recent developments in chemical strategies","volume":"62","author":"Dhanda","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112931_bib27","first-page":"39","article-title":"Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review","volume":"10","author":"Kmeid","year":"2015","journal-title":"Core Evid."},{"key":"10.1016\/j.ejmech.2020.112931_bib28","series-title":"Antibacterials: Volume II","first-page":"27","author":"Fisher","year":"2018"},{"key":"10.1016\/j.ejmech.2020.112931_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112931_bib30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, Chemistry, and in\u00a0vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112931_bib31","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1039\/C6MD00232C","article-title":"Recent Advances in the rational design and optimization of antibacterial agents","volume":"7","author":"Jones","year":"2016","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2020.112931_bib32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/am.17.6.783-786.1969","article-title":"Effect of beta-lactamase location in Escherichia coli on penicillin synergy","volume":"17","author":"Neu","year":"1969","journal-title":"Appl. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112931_bib33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112931_bib34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2174\/138920312804871120","article-title":"Microbe-host interactions: structure and role of Gram-negative bacterial porins","volume":"13","author":"Galdiero","year":"2012","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.ejmech.2020.112931_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbapap.2008.11.005","article-title":"Outer membrane permeability and antibiotic resistance","volume":"1794","author":"Delcour","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2020.112931_bib36","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112931_bib38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1039\/b906679a","article-title":"Chemistry and biology of siderophores","volume":"27","author":"Hider","year":"2010","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2020.112931_bib39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/AAC.17.5.807","article-title":"A\u00a0new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae","volume":"17","author":"Verbist","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib40","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13543784.2018.1426745","article-title":"Cefiderocol: a novel siderophore cephalosporin","volume":"27","author":"Choi","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2020.112931_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/cid\/ciz825","article-title":"The role of iron and siderophores in infection and the development of siderophore antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112931_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13613-015-0061-0","article-title":"Mechanisms of antimicrobial resistance in Gram-negative bacilli","volume":"5","author":"Rupp\u00e9","year":"2015","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.ejmech.2020.112931_bib43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/cid\/ciz827","article-title":"In\u00a0vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112931_bib44","doi-asserted-by":"crossref","first-page":"40262","DOI":"10.1371\/journal.pone.0040262","article-title":"Multi-target drugs: the trend of drug research and development","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2020.112931_bib45","first-page":"441","article-title":"New \u03b2-lactamase inhibitors in the clinic","volume":"2","author":"Papp-Wallace","year":"2016","journal-title":"Infect. Dis. Clin."},{"key":"10.1016\/j.ejmech.2020.112931_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.39.7.1629","article-title":"The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA","volume":"39","author":"Keynan","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0163-7258(99)00027-3","article-title":"Class A beta-lactamases\u2014enzyme-inhibitor interactions and resistance","volume":"83","author":"Yang","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2020.112931_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones\"","volume":"51","author":"Andersson","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-Naphthyridine derivatives. a new class of chemotherapeutic agents","volume":"91","author":"Lesher","year":"1962","journal-title":"J.\u00a0Med. Pharmaceut. Chem."},{"key":"10.1016\/j.ejmech.2020.112931_bib50","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.112931_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones\"","volume":"51","author":"Andersson","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In\u00a0vitro and in\u00a0vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib53","doi-asserted-by":"crossref","first-page":"9611","DOI":"10.1093\/nar\/gkx649","article-title":"Activities of gyrase and topoisomerase IV on positively supercoiled DNA","volume":"45","author":"Ashley","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2020.112931_bib54","first-page":"11","article-title":"DNA topoisomerase: the key enzyme that regulates DNA super structure","volume":"61","author":"Kato","year":"1998","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.ejmech.2020.112931_bib55","first-page":"2741","article-title":"New classification and update on the quinolone antibiotics","volume":"61","author":"King","year":"2000","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.ejmech.2020.112931_bib56","first-page":"112","article-title":"Clinical Ophthalmology: contemporary Perspectives, 9\/e","author":"India","year":"2009","journal-title":". Gupta."},{"key":"10.1016\/j.ejmech.2020.112931_bib57","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/378809","article-title":"Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones","volume":"37","author":"Saravolatz","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112931_bib58","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In\u00a0vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone","volume":"47","author":"Nilius","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib59","doi-asserted-by":"crossref","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","article-title":"DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance","volume":"94","author":"Zhao","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2020.112931_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02317-17","article-title":"Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections","volume":"62","author":"Wagenlehner","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib61","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1128\/AAC.43.12.2969","article-title":"Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group","volume":"43","author":"Lu","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib62","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib63","first-page":"1258","article-title":"Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance","volume":"72","author":"Randall","year":"2017","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Pl\u00e9siat","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2020.112931_bib65","first-page":"23","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Bambeke","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ejmech.2020.112931_bib66","first-page":"63","article-title":"Finafloxacin for the treatment of urinary tract infections","volume":"24","author":"Bartoletti","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2020.112931_bib67","unstructured":"Laponogov, I; Veselkov, D; Pan, X; Selvarajah, J; Crevel, I; Fisher, L; Sanderson, M. Structural Studies of the Drug-Stabilized Cleavage Complexes of Topoisomerase IV and Gyrase from Streptococcus Pneumoniae."},{"key":"10.1016\/j.ejmech.2020.112931_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1060028018786510","article-title":"Ozenoxacin: a novel topical quinolone for impetigo","volume":"52","author":"Wren","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2020.112931_bib69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14787210.2019.1573671","article-title":"Ozenoxacin: a review of preclinical and clinical efficacy","volume":"17","author":"Vila","year":"2019","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ejmech.2020.112931_bib70","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/AAC.45.12.3544-3547.2001","article-title":"Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition","volume":"45","author":"Takei","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib71","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1128\/AAC.01509-13","article-title":"In\u00a0vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant Gram-positive bacteria","volume":"57","author":"L\u00f3pez","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112931_bib72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14787210.2019.1573671","article-title":"Ozenoxacin: a review of preclinical and clinical efficacy","volume":"17","author":"Vila","year":"2019","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.ejmech.2020.112931_bib73","first-page":"54","article-title":"Safety of fluoroquinolones: an update","volume":"13","author":"Mandell","year":"2002","journal-title":"Can. J. Infect Dis."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342030903X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342030903X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:20:48Z","timestamp":1759328448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342030903X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":72,"alternative-id":["S022352342030903X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112931","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacological drug actions of recently FDA approved antibiotics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112931"}}